A Study Comparing Sems Placement With and and Without Biliary Sphincterectomy in Patients With Malignant Biliary Obstruction
A Prospective, Randomized, Multicenter Study Comparing Sems Placement With and and Without Biliary Sphincterectomy in Patients With Malignant Biliary Obstruction (ES vs noES-1)
1 other identifier
interventional
400
1 country
1
Brief Summary
Background and rationale Placement of biliary self expanding metal stent (SEMS) is indicated when malignant common bile duct obstruction is encountered. Currently, there is still controversy regarding the use of endoscopic sphincterotomy (EST) before the placement of biliary stents. EST may facilitate insertion of self expandable metal stent (SEMS) and also help avert the development of pancreatitis from stent-related occlusion of the pancreatic duct. On the other hand, ES is also independently associated with pancreatitis, bleeding, and perforation. Latest European guidelines indicate that EST is not necessary for inserting single plastic or metal biliary stents, nevertheless a more recent meta analysis showed that ES may decrease the rate of PEP. Population and patient selection criteria All the patient referred for endoscopic retrograde cholangiopancreatography (ERCP) due to malignant bile duct obstruction. Study design and study duration Prospective randomized, multicenter study. 18 months. Description of study treatment/product/intervention All the patients will be randomly assigned to undergo ERCP with (Group A) or without (Group B) ES before biliary SEMS placement. All the endoscopic procedures will be performed by experienced endoscopist in the endoscopy suite. All the procedure will be conducted under deep sedation. SEMS placed will be fully covered. Objectives To assess the need for EST before SEMS placement in patients with malignant bile duct obstruction. To evaluate immediate (periprocedural) and delayed (30 days) post ERCP complications including pancreatitis, SEMS migration, bleeding and perforation. Statistical methods, data analysis A sample size analysis to detect superiority at 5% significance level and a power of 80% showed that 500 patients had to be enrolled in each group. Continuous variables such age will be reported in terms of their mean and range, and t-test will be done to test their main difference. X square test or Fisher exact test will be carried out for statistical analysis to compare rates of total complications between the two groups and rates of pancreatitis, bleeding, stent migration and perforation. Wilcoxon Mann-Withney test will be used for comparison of means between 2 continuous variables. A single-tailed P value of less than 0,05 is considered significant. Study time table Project starting date: 15-7-2015 Project completion of patients accrual: 15-10-2016 Project completion of data collection: 15-11-2016 Project data analysis: 15-2-2017 Project presentation of scientific report: 15-4-2017
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jan 2015
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2015
CompletedFirst Submitted
Initial submission to the registry
April 3, 2018
CompletedFirst Posted
Study publicly available on registry
August 14, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2023
CompletedSeptember 21, 2022
September 1, 2022
9 years
April 3, 2018
September 19, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number and type of complications after ERCP.
18 Months
Study Arms (2)
A
OTHERERCP with (Group A) ES before biliary SEMS placement
B
OTHERERCP without (Group B) ES before biliary SEMS placement
Interventions
Eligibility Criteria
You may qualify if:
- Patients referred for endoscopic retrograde cholangiopancreatography
- Malignant bile duct obstruction
- Signed written informed consent
- Age \> 18
You may not qualify if:
- Inability to provide inform consent
- Pregnancy or lactation
- Suspected perforation of the GI tract
- Anatomical alterations due to previous surgery (Billroth surgery)
- Coagulation alterations
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Endoscopy Unit, Gastroenterology Department, Humanitas Research Hospital
Rozzano, Milano, 20089, Italy
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SEQUENTIAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 3, 2018
First Posted
August 14, 2018
Study Start
January 1, 2015
Primary Completion
December 31, 2023
Study Completion
December 31, 2023
Last Updated
September 21, 2022
Record last verified: 2022-09
Data Sharing
- IPD Sharing
- Will not share